ENP107: Compounded Obesity Medications

About this episode

The episode discusses the rise of compounded GLP-1 obesity medications, their popularity, and the safety concerns associated with them.

Technically known as glucagon-like peptide-1 receptor agonists, or GLP-1, these drugs have been around for years for treating diabetes. Now it seems most people think of GLP-1 drugs as medications to lose weight, and these medications are so popular that for a time, supply could not meet demand, leaving many to seek compounded GLP-1 medications, which were more accessible and affordable. However, compounded medications are not FDA-approved, and there are questions regarding their safety and efficacy. What do doctors and patients need to know when considering using compounded obesity medications? To help answer this, host Aaron Lohr talks with Michael Weintraub, MD , an endocrinologist at NYU Langone Division of Endocrinology. Dr. Weintraub serves on the exam writing committee for the American Board of Obesity Medicine. Support for this episode was provided by Lilly. Show notes are available at https://www.endocrine.org/podcast/enp107 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

People in this episode

Host: Aaron Lohr

Guest: Michael Weintraub, MD

Topics covered

• obesity medications
• GLP-1 drugs
• compounded medications
• safety and efficacy
• diabetes treatment

Keywords

• GLP-1
• obesity
• compounded medications
• safety
• efficacy
• diabetes
• endocrinology

Sponsors

Lilly

Mentioned in this episode

Organizations: NYU Langone Division of Endocrinology, American Board of Obesity Medicine

More episodes of Endocrine News Podcast

• ENP111: Addressing the Endocrine Workforce Shortage · February 25, 2026 · 30 min
• ENP110: Hypercortisolism and T2D · January 21, 2026 · 20 min
• ENP109: Anti-Obesity Medications (CME credit available) · January 7, 2026 · 13 min
• ENP108: AI and Robotics in Surgery · December 17, 2025 · 10 min
• ENP106: Reversing Bariatric Surgery · November 12, 2025 · 12 min
• ENP105: Tirzepatide and Menopause · October 29, 2025 · 19 min